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Factors associated with timeliness of
post-primary care referral, diagnosis and
treatment for lung cancer: population-based,
data-linkage study
L F Forrest*,1,2, J Adams1,2, M White1,2 and G Rubin1,3
1Fuse, UKCRC Centre for Translational Research in Public Health, Newcastle University, Newcastle upon Tyne NE2 4AX, UK;
2Institute of Health & Society, Newcastle University, Baddiley Clark Building, Richardson Road, Newcastle upon Tyne NE2 4AX, UK
and 3Wolfson Research Institute, Durham University, Queen’s Campus, Stockton on Tees TS17 6BH, UK
Background: The NHS Cancer Plan for England set waiting time targets for cancer referral (14 days from GP referral to first
hospital appointment) and treatment (31 days from diagnosis, 62 days from urgent GP referral). Interim diagnostic intervals can
also be calculated. The factors that influence timely post-primary care referral, diagnosis and treatment for lung cancer are not
known.
Methods: Northern and Yorkshire Cancer Registry, Hospital Episode Statistics and lung cancer audit data sets were linked.
Logistic regression was used to investigate the factors (socioeconomic position, age, sex, histology, co-morbidity, year of
diagnosis, stage and performance status (PS)) that may influence the likelihood of referral, diagnosis and treatment within target,
for 28 733 lung cancer patients diagnosed in 2006–2010.
Results: Late-stage, poor PS and small-cell histology were associated with a higher likelihood of post-primary care referral,
diagnosis and treatment within target. Older patients were significantly less likely to receive treatment within the 31-day (odds
ratio (OR)¼ 0.79, 95% confidence interval (CI) 0.69–0.91) and 62-day target (OR¼ 0.80, 95% CI 0.67–0.95) compared with younger
patients.
Conclusions: Older patients waited longer for treatment and this may be unjustified. Patients who appeared ill were referred,
diagnosed and treated more quickly and this ‘sicker quicker’ effect may cancel out system socioeconomic inequalities that might
result in longer time intervals for more deprived patients.
Early diagnosis of lung cancer is thought to be important for
improving outcomes. Survival is better for patients diagnosed at an
early stage because they are more likely to be suitable for receipt of
curative treatment (Richards, 2009). Delays between the onset of
cancer symptoms and receipt of treatment could result in potentially
resectable tumours becoming inoperable, and this may contribute to
the poorer survival of UK cancer patients compared with that found
in other European countries (Richards, 2009).
In the United Kingdom, there are a number of different routes
to diagnosis. Three of these diagnostic pathways reflect the urgency
of the referral (emergency presentation at hospital or via the GP,
urgent 2-week GP referral and other GP referral; Elliss-Brookes
et al, 2012). Theoretical models of the pathway from first symptom
to cancer treatment identify key diagnostic (including referral) and
treatment intervals, and related healthcare system (primary and
secondary care) settings (Hansen et al, 2008; Walter et al, 2012).
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An early model of cancer delay, the Anderson model, attributed
the majority of delay to patient factors (Andersen et al, 1995).
The model has been updated to also consider tumour and healthcare
system factors (Walter et al, 2012), as these are likely to make
important contributions to the time to diagnosis and treatment.
Three intervals are currently the subject of performance
management within the NHS in England. Since 2000, urgent
referrals for suspected cancer have been required to have a first
hospital appointment (FHA) within 14 days from the date of GP
referral (referral interval). Since 2005, target intervals of 62 days
from the date of urgent GP referral to first treatment and 31 days
from diagnosis (decision-to-treat) to first treatment (treatment
intervals) have been in place (Department of Health, 2000).
Interim diagnostic interval targets of 31 days from GP referral and
17 days from FHA can be inferred (Figure 1).
Although research has explored factors that might influence the
time spent within pathway intervals for breast and colorectal
cancer (Ramirez et al, 1999; Mitchell et al, 2008), there is little
definitive evidence on the factors that are important for lung
cancer. In a review of potential reasons for delay in lung cancer
care (14 studies), variables including stage, co-morbidity, atypical
symptoms, income, age, sex, rural residence and distance to
healthcare were examined (Olsson et al, 2009). The authors were
unable to draw any clear conclusions as they reported that the
quality of included studies was poor. The majority of studies
considered only single factors and did not take into account
potential confounders such as age, stage, histology and co-
morbidity (Olsson et al, 2009).
In this study, cancer registry, Hospital Episode Statistics (HES)
and lung cancer audit (LUCADA) data sets were linked to
investigate the factors (socioeconomic position (SEP), age, sex,
histology, co-morbidity, year of diagnosis, stage and performance
status (PS)) that may influence the likelihood of post-primary care
referral, diagnosis and treatment within target times.
MATERIALS AND METHODS
Data sources and linkage. We analysed a linked data set reported
previously (Forrest et al, 2014c). Data for 29 385 patients with a
primary diagnosis of lung cancer (ICD10 C33 and C34), diagnosed
between 1 January 2006 and 31 December 2010, were obtained
from the Northern and Yorkshire Cancer Registry and Information
Centre (NYCRIS, 2012). Of these, 652 had tumour registration
based on death certification only and so were excluded from
analyses, leaving an eligible cohort of 28 733.
Data on SEP, age, sex, histology, year of diagnosis, GP referral
date, FHA date, diagnosis date, treatment dates and details of
receipt of treatment (surgery, chemotherapy and radiotherapy)
were obtained from the registry data. Co-morbidity data were
obtained from HES and used to calculate a co-morbidity score.
Data on stage and PS were obtained from the national LUCADA, a
non-mandatory register of clinical information on patients
diagnosed with lung cancer comprising a subset of registry patients
(66% nationally in 2006, increasing to 93% in 2010; NHS
Information Centre, 2012).
Records were allocated a unique, randomly generated, key
number, derived from the NHS number by NYCRIS. Data from the
three data sources were anonymised and supplied by NYCRIS. The
HES and LUCADA data were then linked to the registry data using
this key.
Variables of interest. SEP was measured using the income
domain of the Index of Multiple Deprivation (IMD; HM
Government, 2013), grouped into quintiles for analysis. This is
an area-based measure of SEP, where Q5 is the most deprived
and Q1 the least deprived. Age at diagnosis was categorised into
four groups for analysis: o60, 60–69, 70–79 and 80þ years.
Year of diagnosis was included to examine system changes over
time.
Histology was classified as confirmed non-small-cell lung cancer
(NSCLC), including adenocarcinoma, large-cell carcinoma, non-
small-cell carcinoma and squamous cell carcinoma subtypes;
small-cell lung cancer (SCLC); and other histology (including
unspecified carcinoma, neoplasm, other specified carcinomas and
carcinoid tumours).
A weighted co-morbidity score was calculated by NYCRIS using
the Charlson co-morbidity index (CCI; Charlson et al, 1987) a
validated instrument used previously to determine co-morbidity in
cancer patients. No HES-linked data were available for patients
diagnosed in 2009–2010 as, due to national problems in calculating
the co-morbidity score, there was a time lag in data availability.
Patients without a CCI score were split into those who did and did
not have a HES linkage. CCI score was categorised as 0, 1–2, 3þ ,
missing (HES-linked data available but no CCI score recorded) or
unavailable (no HES-linked data available).
Stage was assigned using the TNM staging system and
categorised as I, II, III, IV or missing (Sobin and Wittekind,
1997). PS is a measure of general well-being for cancer patients,
assessed on a scale of 0 (asymptomatic) to 4 (bedridden) using the
Eastern Co-operative Group PS scale (NICE, 2005) and was
categorised as 0, 1–2, 3–4 or missing. Stage and PS data were
entered into LUCADA by trusts participating in the audit.
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Figure 1. Intervals and target times on the cancer diagnosis and treatment pathway (adapted from Hansen et al, 2008).
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Table 1 shows the referral and treatment intervals included in
this study (Forrest et al, 2014b), alongside target times for these.
The referral interval was categorised as: GP referral date to FHA
p14 days (within target), GP referral 414 days and no GP
referral. Interim diagnostic intervals and the target times that can
be inferred are also shown in Table 1. These were calculated as
follows: GP referral to diagnosis (62 31¼ 31 days) and FHA to
diagnosis (31 14¼ 17 days).
Between 2006 and 2009, date of diagnosis was determined by
cancer registries as the first time the tumour was identified either by
imaging or histology in the case notes. In 2010, UK Association of
Cancer Registry guidance was followed. The guidance uses a priority
hierarchy with six categories to determine date of diagnosis; the date
of histological or cytological confirmation of malignancy (which can
be derived from three different hierarchical time points); date of
hospital admission; and down to, with lowest priority, date of death
if cancer is only identified at autopsy (Weller et al, 2012).
Analysis. Median referral, diagnostic and treatment times, with
inter-quartile range (IQR), were calculated for each time interval.
The number and percentage of patients referred, diagnosed and
treated within target were also calculated for each time interval, by
each included variable. Differences in the likelihood of referral,
diagnosis and treatment within target by SEP, age, sex, histology,
year of diagnosis, co-morbidity score, stage and PS were explored
using logistic regression models mutually adjusted for all co-
variables. As the aim was to explore which factors might be
important for time spent within each interval, the variable selection
procedure was based on an underlying conceptual framework
rather than on formal stepwise methods (Kirkwood and Sterne,
2003). Variables were selected for inclusion if they had previously
been identified as potentially important. Referral interval was
adjusted for in the models for the FHA to diagnosis and diagnosis
to treatment intervals. Type of first treatment was included in the
models for treatment intervals. Receipt of treatment was included
in the models for diagnostic intervals.
Patients were eligible for inclusion within an interval if they had
a date recorded for the interval start and end point. Records were
excluded from analyses if they had a negative interval for any time
period, for example, if they had a GP referral date later than
diagnosis date, as this was likely to be a data entry error. Records
were included if they had 0 time between dates (for example,
treatment date was recorded on the same day as date of diagnosis).
To include these records in the analysis, 0 time intervals were
recoded as 0.1. Analysis was also restricted to those cases with
interval dates within 1 year of the previous interval end point.
Odds ratios (ORs) with 95% confidence intervals (CIs) for the
likelihood of receipt of referral, diagnosis and treatment within
target for each variable were reported. Likelihood ratio tests were
used to determine the overall significance of each categorical
variable. Analysis was carried out in Stata v12.0 (StataCorp, College
Station, TX, USA).
RESULTS
Data and descriptive statistics. Of the full cohort (28 733), 7769
(27.0%) had stage and 8885 (30.9%) had a PS score recorded in
LUCADA, and 18 650 (64.9%) had a linked HES record, of whom
8475 (29.5%) had a CCI score recorded. All 28 733 patients had a
date of diagnosis, 28 704 (99.9%) had FHA date recorded, 15 452
(53.8%) had a GP referral date and 15 373 (53.5%) received any
treatment within 1 year of diagnosis. Once patients with negative
intervals and intervals longer than 1 year were excluded, 14 507
patients had GP referral and FHA dates recorded, and also GP
referral and diagnosis dates; 27 555 had FHA and diagnosis dates;
14 692 had diagnosis and treatment dates; and 9542 had GP
referral and treatment dates. The demographic and clinical
characteristics of the patients included in each analysis are shown
in columns 1–4 of Tables 2–4.
Referral interval: likelihood of FHA within 14 days from GP
referral. Median time from GP referral to FHA was 10 days (IQR
6–17), n¼ 14 507. Of those referred by their GP, 70.4% had FHA
within the 14-day target from GP referral. The data set included
both urgent and non-urgent referrals.
Greater deprivation was associated with a lower likelihood of
FHA within 14 days of GP referral in the multivariable analysis
(OR¼ 0.83, CI 0.73–0.94), but the lowest likelihood was for those
in the middle SEP groups. No simple pattern by age emerged. Late-
stage cancer, SCLC, poor PS and referral post-2006 were associated
with increased likelihood of FHA within 14 days of referral, but sex
and CCI score were not (Table 2).
Diagnostic interval: likelihood of diagnosis within 31 days from
GP referral. In those patients with GP referral and diagnosis dates
(n¼ 14 507), median time from GP referral to diagnosis was 13 days
(IQR 7–24) and 82.6% were diagnosed within the 31-day target.
Neither SEP nor age was associated with likelihood of diagnosis
within 31 days of GP referral overall, although those in the middle
SEP groups had significantly lower likelihood of diagnosis within
31 days (Table 3). Patients with poorer PS, later-stage cancer and
those with SCLC had an increased likelihood of diagnosis within 31
days of GP referral. Those diagnosed in 2007–2009 had a higher
likelihood of diagnosis within 31 days.
Diagnostic interval: likelihood of diagnosis within 17 days from
FHA. In those patients with FHA and diagnosis dates
(n¼ 27 555), median time from FHA to diagnosis was 0 days
(IQR 0–0) and 91.4% of patients were diagnosed within 17 days.
Neither SEP nor age was associated with likelihood of diagnosis
within 17 days of FHA (Table 3). Patients with poorer PS, later-
stage cancer and those with SCLC had an increased likelihood of
timely diagnosis. Those diagnosed in 2007–2009 had a higher
likelihood of timely diagnosis.
Treatment interval: likelihood of treatment within 31 days from
diagnosis. Of the 14 692 patients who were treated within 1 year,
median time to treatment was 35 days (IQR 21–55) and 43.1%
(6333) were treated within the 31-day target time from diagnosis
(Table 4).
There was no association between SEP and likelihood of
treatment within 31 days of diagnosis (P¼ 0.41). Patients
diagnosed with SCLC were significantly more likely to receive
treatment within target compared with those diagnosed with
NSCLC (OR¼ 4.53, CI 4.06–5.04). Older patients were signifi-
cantly less likely to receive treatment within the 31-day target
(OR¼ 0.79, CI 0.69–0.91).
Table 1. Referral, diagnostic and treatment intervals
Interval Definition of interval
Target
time
(days)
Referral GP referral date to first hospital appointment date 14
Diagnostic GP referral date to diagnosis datea 31b
First hospital appointment date to diagnosis datea 17b
Treatment Diagnosis date to first treatment date 31
GP referral date to first treatment date 62
Abbreviation: GP¼general practitioner.
aInterim target intervals.
bCalculated interim target times.
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Those receiving surgery were less likely to receive treatment
within target times compared with those receiving chemotherapy.
Those with poor PS and later-stage cancer were more likely to
receive treatment within target.
Treatment interval: likelihood of treatment within 62 days from
GP referral. Of the 9542 patients who were referred by their GP
and had treatment, median time from GP referral to first treatment
date was 56 days (IQR 39–79) and 61.2% of those who received
treatment were treated within 62 days (Table 4), although we had
no details of how many of these were urgent referrals. An overall
association between SEP and likelihood of starting treatment
within the target time was found (P¼ 0.04), with those in the
middle SEP groups significantly less likely to start treatment within
62 days.
Early-stage patients, older patients and those receiving surgery
were significantly less likely to start treatment within 62 days,
whereas late-stage patients, those with poor PS and those receiving
chemotherapy, were more likely to do so. The likelihood of receiving
treatment within guidelines significantly improved over time.
Table 2. Post-primary care referral interval: likelihood of FHA within 14 days of GP referrala
GP referral & FHA date FHA within 14 days of GP referral Multivariable analysis (n¼14507, R2¼7.09)b
N N % OR 95% CI P-value
IMD 14 507 10218 70.4 0.0004
1 (least deprived) 1709 1263 73.9 1.00
2 2028 1430 70.5 0.85 0.73 0.99
3 2456 1714 69.8 0.79 0.68 0.91
4 3447 2363 68.6 0.74 0.65 0.85
5 (most deprived) 4867 3448 70.8 0.83 0.73 0.94
Age range 14 507 10218 70.4 0.019
o60 2008 1450 72.2 1.00
60–69 4143 2975 71.8 0.97 0.86 1.10
70–79 5263 3628 68.9 0.86 0.76 0.97
80þ 3093 2165 70.0 0.89 0.77 1.02
Sex 14 507 10218 70.4 0.60
Female 6601 4681 70.9 1.00
Male 7906 5537 70.0 1.02 0.95 1.10
Histology 14 507 10218 70.4 o0.001
NSCLC 8803 6077 69.0 1.00
SCLC 1898 1479 77.9 1.64 1.45 1.85
Other 3806 2662 69.9 1.03 0.94 1.13
Diagnosis year 14 507 10218 70.4 o0.001
2006 2465 1235 50.1 1.00
2007 2575 1475 57.3 1.34 1.20 1.50
2008 3062 2479 81.0 4.26 3.77 4.81
2009 3156 2501 79.3 4.39 3.79 5.09
2010 3249 2528 77.8 3.94 3.37 4.60
CCI score 14 507 10218 70.4 o0.001
0 1899 1279 67.4 1.00
1–2 1389 936 67.4 0.89 0.76 1.04
3þ 294 201 68.4 0.80 0.60 1.05
Missing 5384 3560 66.1 1.24 1.10 1.40
Unavailable 5541 4242 76.6 0.96 0.83 1.10
Stage 14 507 10218 70.4 o0.001
I 764 504 66.0 1.00
II 393 282 71.8 1.32 1.00 1.73
III 1558 1169 75.0 1.49 1.22 1.81
IV 2307 1848 80.1 1.77 1.47 2.15
Missing 9485 6415 67.6 1.45 1.19 1.76
Performance status 14 507 10218 70.4 0.001
0 1351 990 73.3 1.00
1–2 3198 2394 74.9 1.02 0.88 1.19
3–4 1217 988 81.2 1.36 1.11 1.67
Missing 8741 5846 66.9 0.94 0.79 1.12
Abbreviations: CCI score¼Charlson co-morbidity score; CI¼ confidence interval; FHA¼ first hospital appointment; GP¼general practitioner; IMD¼ Index of Multiple Deprivation;
NSCLC¼ non-small-cell lung cancer; OR¼odds ratio; SCLC¼ small-cell lung cancer.
aExcluding those with FHA 41 year from GP referral, diagnosis 41 year from FHA, any negative time interval.
bMutually adjusted for socioeconomic position, age, sex, histology, year of diagnosis, co-morbidity score, stage and PS.
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Table 3. Diagnostic interval: likelihood of diagnosis within 31 days from GP referral, and of diagnosis within 17 days from FHAa
GP referral to diagnosis FHA to diagnosis
GP
referral &
diagnosis
date
Diagnosis
within 31 days
of GP referral
Multivariable analysis
(n¼14507, R2¼4.56)b
FHA &
diagnosis
date
Diagnosis
within 17 days
of FHA
Multivariable analysis
(n¼27555, R2¼8.67)c
N N % OR 95% CI P-value N N % OR 95% CI P-value
IMD 14507 11978 82.6 0.08 27555 25197 91.4 0.65
1 (least deprived) 1709 1436 84.0 1.00 3257 2990 91.8 1.00
2 2028 1669 82.3 0.90 0.75 1.07 4020 3666 91.2 0.91 0.77 1.09
3 2456 2006 81.7 0.84 0.71 1.00 4658 4239 91.0 0.88 0.75 1.04
4 3447 2820 81.8 0.83 0.71 0.97 6437 5887 91.5 0.90 0.77 1.05
5 (most deprived) 4867 4047 83.2 0.94 0.80 1.09 9183 8415 91.6 0.93 0.80 1.08
Age range 14507 11978 82.6 0.43 27555 25197 91.4 0.89
o60 2008 1661 82.7 1.00 3503 3166 90.4 1.00
60–69 4143 3437 83.0 1.06 0.91 1.22 7262 6562 90.4 1.01 0.88 1.17
70–79 5263 4314 82.0 0.96 0.84 1.11 9830 8989 91.4 1.01 0.88 1.16
80þ 3093 2566 83.0 0.97 0.83 1.15 6960 6480 93.1 0.96 0.82 1.13
Sex 14 507 11978 82.6 0.009 27555 25197 91.4 0.03
Female 6601 5410 82.0 1.00 12695 11571 91.2 1.00
Male 7906 6568 83.1 1.13 1.03 1.23 14860 13626 91.7 1.11 1.01 1.21
Histology 14 507 11978 82.6 o0.001 27555 25197 91.4 o0.001
NSCLC 8803 7134 81.0 1.00 14484 12915 89.2 1.00
SCLC 1898 1674 88.2 1.77 1.52 2.07 3350 3114 93.0 1.63 1.41 1.89
Other 3806 3170 83.3 1.06 0.94 1.19 9721 9168 94.3 1.45 1.29 1.64
Diagnosis year 14 507 11978 82.6 o0.001 27555 25197 91.4 o0.001
2006 2465 1895 76.9 1.00 5440 5082 93.4 1.00
2007 2575 2139 83.1 1.49 1.29 1.71 5619 5298 94.3 1.16 0.99 1.35
2008 3062 2706 88.4 2.25 1.94 2.61 5541 5223 94.3 1.14 0.97 1.34
2009 3156 2754 87.3 2.41 2.03 2.87 5489 5111 93.1 1.13 0.95 1.36
2010 3249 2484 76.5 1.05 0.89 1.26 5466 4483 82.0 0.34 0.29 0.41
CCI score 14 507 11978 82.6 o0.001 27555 25197 91.4 o0.001
0 1899 1527 80.4 1.00 3841 3492 90.9 1.00
1–2 1389 1102 79.3 0.86 0.72 1.02 3377 3082 91.3 0.94 0.80 1.12
3þ 294 223 75.9 0.68 0.50 0.92 886 798 90.1 0.84 0.65 1.08
Missing 5384 4591 85.3 1.53 1.32 1.77 9897 9367 94.6 1.54 1.33 1.80
Unavailable 5541 4535 81.8 1.10 0.94 1.29 9554 8458 88.5 1.16 1.00 1.35
Stage 14507 11978 82.6 o0.001 27555 25197 91.4 o0.001
I 764 539 70.6 1.00 1116 879 78.8 1.00
II 393 304 77.4 1.52 1.14 2.03 526 434 82.5 1.46 1.10 1.92
III 1558 1313 84.3 2.10 1.70 2.60 2172 1942 89.4 2.28 1.85 2.81
IV 2307 2053 89.0 2.91 2.36 3.60 3583 3340 93.2 3.30 2.68 4.06
Missing 9485 7769 81.9 1.63 1.32 2.02 20158 18602 92.3 1.71 1.39 2.11
Performance status 14 507 11978 82.6 0.0007 27555 25197 91.4 0.002
0 1351 1069 79.1 1.00 1759 1481 84.2 1.00
1–2 3198 2675 83.7 1.22 1.03 1.44 4631 4107 88.7 1.17 0.99 1.39
3–4 1217 1085 89.2 1.66 1.30 2.12 2077 1952 94.0 1.44 1.13 1.83
Missing 8741 7149 81.8 1.18 0.97 1.44 19088 17657 92.5 1.43 1.17 1.73
Any treatmentd 14507 11978 82.6 o0.001 27555 25197 91.4 o0.001
No 4974 4241 85.3 1.00 12863 12228 95.1 1.00
Yes 9533 7737 81.2 0.76 0.67 0.85 14692 12969 88.3 0.45 0.40 0.51
GP referral date 14 507 11978 82.6 27 555 25197 91.4 0.79
No 13048 12105 92.8 1.00
Yes 14 507 13092 90.3 0.99 0.90 1.09
Abbreviations: CCI score¼Charlson co-morbidity score; CI¼ confidence interval; FHA¼ first hospital appointment; GP¼general practitioner; IMD¼ Index of Multiple Deprivation;
NSCLC¼ non-small-cell lung cancer; OR¼odds ratio; SCLC¼ small-cell lung cancer.
aExcluding those with FHA 41 year from GP referral, diagnosis 41 year from FHA, any negative time interval.
bMutually adjusted for socioeconomic position (SEP), age, sex, histology, year of diagnosis, co-morbidity score, stage and PS.
cMutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS and GP referral date.
dWithin 1 year of diagnosis.
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Table 4. Treatment interval: likelihood of treatment within 31 days from diagnosis, and of treatment within 62 days from GP referrala
Diagnosis to treatment GP referral to treatment
Diagnosis
&
treatment
date
Treatment
within 31 days
of diagnosis
Multivariable analysis
(n¼14692, R2¼9.64)b
GP
referral &
treatment
date
Treatment
within 62 days
of GP referral
Multivariable analysis
(n¼9542, R2¼9.18)c
N N % OR 95% CI P-value N N % OR 95% CI P-value
IMD 14692 6333 43.1 0.41 9542 5839 61.2 0.04
1 (least deprived) 1844 822 44.6 1.00 1186 760 64.1 1.00
2 2207 961 43.5 0.97 0.84 1.10 1381 850 61.6 0.89 0.75 1.06
3 2493 1060 42.5 0.89 0.78 1.02 1611 969 60.2 0.83 0.70 0.97
4 3353 1457 43.5 0.94 0.83 1.07 2186 1310 59.9 0.79 0.68 0.92
5 (most deprived) 4795 2033 42.4 0.91 0.81 1.03 3178 1950 61.4 0.88 0.75 1.01
Age range 14692 6333 43.1 o0.001 9542 5839 61.2 o0.001
o60 2795 1356 48.5 1.00 1749 1172 67.0 1.00
60–69 5071 2277 44.9 0.90 0.81 0.99 3313 2105 63.5 0.93 0.81 1.05
70–79 5145 2052 39.9 0.75 0.68 0.83 3355 1913 57.0 0.73 0.64 0.83
80þ 1681 648 38.6 0.79 0.69 0.91 1125 649 57.7 0.80 0.67 0.95
Sex 14 692 6333 43.1 0.19 9542 5839 61.2 0.11
Female 6611 2958 44.7 1.00 4260 2592 60.9 1.00
Male 8081 3375 41.8 0.95 0.89 1.02 5282 3247 61.5 1.07 0.98 1.17
Histology 14 692 6333 43.1 o0.001 9542 5839 61.2 o0.001
NSCLC 10170 3647 35.9 1.00 6864 3947 57.5 1.00
SCLC 2499 1863 74.6 4.53 4.06 5.04 1554 1313 84.5 3.05 2.61 3.57
Other 2023 823 40.7 1.27 1.14 1.41 1124 579 51.5 0.87 0.76 0.99
Diagnosis year 14 692 6333 43.1 o0.001 9542 5839 61.2 0.14
2006 2910 1294 44.5 1.00 1659 965 58.2 1.00
2007 2960 1239 41.9 0.89 0.80 0.99 1734 1020 58.8 1.02 0.88 1.18
2008 2870 1035 36.1 0.65 0.58 0.73 1967 1213 61.7 1.10 0.96 1.27
2009 3001 1133 37.8 0.71 0.62 0.83 2040 1258 61.7 1.17 0.97 1.41
2010 2951 1632 55.3 1.60 1.37 1.88 2142 1383 64.6 1.28 1.05 1.57
CCI score 14 692 6333 43.1 0.45 9542 5839 61.2 o0.001
0 2211 914 41.3 1.00 1315 776 59.0 1.00
1–2 1537 580 37.7 0.91 0.79 1.05 828 426 51.5 0.77 0.64 0.93
3þ 330 137 41.5 1.07 0.83 1.37 147 74 50.3 0.72 0.50 1.03
Missing 5843 2434 41.7 1.01 0.90 1.13 3834 2363 61.6 1.12 0.97 1.30
Unavailable 4771 2268 47.5 1.03 0.90 1.17 3418 2200 64.4 1.11 0.94 1.32
Stage 14 692 6333 43.1 o0.001 9542 5839 61.2 o0.001
I 870 218 25.1 1.00 626 233 37.2 1.00
II 384 94 24.5 0.86 0.65 1.15 314 136 43.3 1.09 0.82 1.45
III 1529 567 37.1 1.36 1.11 1.66 1176 756 64.3 1.61 1.29 2.00
IV 1909 1024 53.6 2.52 2.07 3.07 1366 1067 78.1 2.87 2.29 3.60
Missing 10 000 4430 44.3 1.82 1.49 2.22 6060 3647 60.2 1.65 1.32 2.07
Performance status 14 692 6333 43.1 0.0001 9542 5839 61.2 0.02
0 1599 630 39.4 1.00 1247 750 60.1 1.00
1–2 3417 1502 44.0 1.11 0.97 1.27 2476 1636 66.1 1.08 0.93 1.27
3–4 447 247 55.3 1.66 1.31 2.10 296 212 71.6 1.31 0.96 1.77
Missing 9229 3954 42.8 1.00 0.85 1.16 5523 3241 58.7 0.88 0.73 1.06
First treatmentd 14692 6333 43.1 o0.001 9542 5839 61.2 o0.001
Chemotherapy 6587 3470 52.7 1.00 4486 3273 73.0 1.00
Surgery 2687 864 32.2 0.76 0.68 0.85 1748 654 37.4 0.37 0.32 0.42
Radiotherapy 5418 1999 36.9 0.77 0.70 0.84 3308 1912 57.8 0.73 0.66 0.82
GP referral 14 692 6333 43.1 o0.001
No GP referral date 5159 2354 45.6 1.00
FHA p14 days 6683 2933 43.9 0.92 0.85 1.00
FHA 414 days 2850 1046 36.7 0.74 0.67 0.82
Abbreviations: CCI score¼Charlson co-morbidity score; CI¼ confidence interval; FHA¼ first hospital appointment; GP¼general practitioner; IMD¼ Index of Multiple Deprivation;
NSCLC¼ non-small-cell lung cancer; OR¼odds ratio; SCLC¼ small-cell lung cancer.
aExcluding those with FHA 41 year from GP referral, diagnosis 41 year from FHA, any negative time interval.
bMutually adjusted for socioeconomic position (SEP), age, sex, histology, year of diagnosis, co-morbidity score, stage, PS and GP referral.
cMutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage and PS.
dWithin 1 year of diagnosis.
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DISCUSSION
Principal findings. To our knowledge, this is the first study to
examine factors associated with referral, diagnosis and treatment
within target for lung cancer in England. Generally, those with
SCLC, those with poorer PS, patients diagnosed in more recent
years, and those with more advanced stage cancer were more likely
to have post-primary care referral, diagnosis and treatment within
target. Older patients were less likely to receive first treatment
within the target time. Patients undergoing surgery and radio-
therapy as their first treatment were less likely to receive treatment
within target than those receiving chemotherapy as a first
treatment.
Socioeconomic inequalities in the time from GP referral to FHA,
diagnosis and treatment were found, but were not present for the
interim intervals from FHA to diagnosis or from diagnosis to
treatment. This would suggest that SEP inequalities originate from
the GP referral to FHA interval. However, a linear trend was not
seen. Patients in the middle SEP groups were less likely to receive
FHA, diagnosis or treatment within target, compared with the least
deprived SEP group, but this was not consistently observed for the
most deprived SEP group.
Strengths and weaknesses. The use of multiple data set linkage is
a strength of this study. There are good data completeness and
validity within the registry data set. Linkage to HES and LUCADA
data allowed inclusion of a wide range of factors that are
potentially important for post-primary care referral, diagnosis
and treatment within target for lung cancer. Previous studies
examining lung cancer delay mainly conducted only univariable
analyses and did not include potential confounders such as age,
stage, histology and co-morbidity (Olsson et al, 2009). We were
able to take all these factors, as well as others such as PS and SEP,
into account. However, a lack of concordance in recording of data
between registry and LUCADA data sets has been found (Riaz
et al, 2010).
The type of referral route may influence time to diagnosis and
treatment. Nearly half of the patients (46%) did not have a GP
referral date recorded, but it was not possible to determine from
our data how many of these patients had been referred via a
different route, how many had a GP referral but the date was not
recorded or which were urgent GP referrals. A large study
examining routes to diagnosis also found that low numbers (41%)
of lung cancer patients were referred via their GP (as urgent or
non-urgent referrals; Elliss-Brookes et al, 2012). Those who did
have a GP date had longer time to treatment than those who did
not. This reflects previous findings (Allgar and Neal, 2005) and
suggests that those without a GP referral date may be presenting as
emergency cases and thus receive more urgent investigation and
treatment.
We examined the interim diagnostic interval from FHA to
diagnosis. However, the FHA and diagnosis date often appeared
to be recorded as the same date, which may be due to variability
in the recording of date of diagnosis in the registry data set. A
number of different dates can be used to determine date of
diagnosis. Inconsistent application of the rules could affect
calculation of the diagnostic and treatment intervals and thus
introduce error, although there is no evidence to suggest bias in
recording. It is possible that, for those without a GP referral date,
the FHA may be an emergency hospital visit where diagnosis is
made on that day. Another UK study also found that the median
time from FHA to diagnosis was 0 days for lung cancer and for
five other cancer types (Allgar and Neal, 2005) using patient
survey data. As the same result was found using two different data
sources, this suggests that many patients do receive their
diagnosis at the FHA.
The high levels of missing data for stage, PS and co-morbidity
were a weakness of the study and the inclusion of ‘missing’
categories for these variables may result in bias. Multiple
imputation was not possible as over 50% of the data were missing
for these variables (White et al, 2011). However, although a high
proportion of missing data may make absolute estimates of
proportions unreliable, it is unlikely to matter substantially for
estimation of the independent effects of each variable, within each
fully adjusted model. As the majority of other studies did not
conduct multivariable analysis (Olsson et al, 2009), there is little
other research to compare our results to, in order to assess whether
missing data could account for any of the observed patterns. SEP
was measured at an area-based level using IMD, which is a further
limitation, as area-based measures may not accurately reflect
individual-level circumstances.
Interpretation of results and comparison with other studies
Diagnostic interval. Diagnostic delay has been implicated as a
factor that contributes to the poorer survival of UK cancer patients
compared with the European average (Richards, 2009). However,
the impact of delay on lung cancer survival is unclear (Jensen et al,
2002) and other studies suggest that those who experience shorter
system delay may, in fact, have poorer lung cancer survival as they
are at the ‘sicker’ end of the spectrum (Myrdal et al, 2004; Forrest
et al, 2014a), with symptoms that result in more urgent referral and
diagnosis.
Two studies from Sweden (Berglund et al, 2010) and Denmark
(Dalton et al, 2011), countries with similar healthcare systems to
the United Kingdom, found socioeconomic inequalities in time
from referral to diagnosis, with higher SEP patients having more
prompt diagnosis. We found socioeconomic inequalities from GP
referral to diagnosis and, within this interval, from GP referral to
FHA, but not from FHA to diagnosis. This replicates previous UK
findings (Neal and Allgar, 2005). The evidence therefore suggests
that socioeconomic diagnostic inequalities are found in the GP
referral to FHA interval rather than the secondary care FHA to
diagnostic interval.
Referral interval. It has been suggested that socioeconomic
differences in communicating and presenting cancer symptoms
to health professionals may result in longer delays for those who
are less ‘convincing’ (Corner and Brindle, 2011). Lower SEP
patients may be less articulate, have poorer health literacy and be
more culturally distant from doctors, whereas more educated
cancer patients are better able to describe symptoms and thus
speed up the referral process (Hansen et al, 2008; Forrest, 2013).
However, a nonlinear trend in socioeconomic inequalities in the
likelihood of being referred to secondary care within time interval
guidelines was found. Those in the middle SEP groups were less
likely to receive timely referral than those in the least deprived SEP
group, but this was not seen for those in the most deprived SEP
group.
The waiting time paradox suggests that sicker people are
referred more quickly as they are more obviously ill, but also less
likely to survive (Torring et al, 2011), and so results in a positive
association bias. Our findings of an inverse relationship between
PS and likelihood of referral within target support this theory. This
may be a possible explanation as to why the most deprived patients
were not significantly less likely to receive a timely referral or
diagnosis compared with the most affluent, as we might have
expected. Patients with lower SEP had poorer PS (results not
shown) and so were likely to be in generally poorer health. The
results of this ‘sicker quicker’ effect may, therefore, act to effectively
‘cancel out’ any potential system inequalities that might result in
longer referral and diagnosis intervals for more deprived patients.
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In a previous study, age and sex did not appear to influence the
likelihood of urgent referral for lung cancer (Allgar et al, 2006). We
also found that sex was not associated with likelihood of timely
referral and no clear pattern of referral was found by age.
Patients subsequently diagnosed with later-stage cancer and
those with poor PS had a higher likelihood of being referred within
14 days. Stage, PS and co-morbidity score can all be considered as
proxy measures for how ill a patient is, which may influence
referral behaviour. Urgent referral requires the presence of ‘alarm’
symptoms that are more likely to be present as the disease
advances.
A previous small study found that co-morbidity delayed
diagnosis in around 23% of lung cancer patients seen by GPs
(Bjerager et al, 2006). Symptoms (for example cough, weight loss
or breathlessness) may be ascribed to a known co-morbidity (for
example, COPD) rather than lung cancer. However, no clear-cut
pattern was observed in referral or diagnosis time by co-morbidity
score in this study, but those with poorer PS had increased
likelihood of referral and diagnosis within target.
Both CCI score and PS can be used as proxy measures of general
well-being and it is difficult to say how well they capture this
(Forrest et al, 2014b). CCI is a validated instrument for measuring
co-morbidity (Charlson et al, 1987) but it is a fairly crude measure
and, as it only contains details of conditions requiring in-patient
care, it is likely to underestimate co-morbidity (Forrest et al,
2014c). It may be that the number of co-morbidities is not a
particularly sensitive measure of patient well-being and PS may be
a better marker.
Treatment interval. SEP was not associated with treatment within
target from diagnosis. However, in the referral to treatment
interval, those in the middle SEP groups appeared less likely to
receive treatment within the 62-day guidelines, compared with the
least deprived group. Those with SCLC, later-stage cancer and
poorer PS were more likely to receive timely treatment within
target. Again the ‘sicker quicker’ phenomenon may explain this.
The previous evidence for time spent on the care pathway by
age is mixed, with a UK study using patient survey data finding
that younger patients had longer time intervals (Neal and Allgar,
2005). In agreement with a Swedish study using medical record
data, which found that older patients had longer time to lung
cancer treatment (Lovgren et al, 2008), we also found that older
patients were significantly less likely to receive treatment within
target time. This was seen even when factors such as stage, co-
morbidity and PS were taken into account, which might indicate
that older patients are experiencing unwarranted delays.
Implications for policy and practice, and further research. Due to
changes in the way that date of diagnosis was calculated in 2010, it
was difficult to be sure that any differences seen in this year were
system changes as a result of the introduction of targets or just due
to the change in rules for determining date of diagnosis. Consistent
determination of GP referral, FHA, diagnosis and treatment dates
and robust systems for reliably capturing this data are necessary for
accurate calculation of referral, diagnosis and treatment intervals.
However, as improvements over time were found pre-2010, it
does appear that introduction of NICE guideline targets (NICE,
2005) has resulted in a greater proportion of patients being
referred, diagnosed and treated within target times.
In this study, patients who underwent surgery as a first
treatment were less likely to be treated within target compared with
patients undergoing chemotherapy. It has been suggested that
those who receive curative surgery may undergo a longer period of
preliminary investigation with a greater number of diagnostic and
staging procedures (Devbhandari et al, 2007). However, there may
be capacity limitations on the pathway to surgery and future
research should investigate whether it is possible to improve the
timeliness of surgical treatment.
Older lung cancer patients were less likely to be treated within
target times. Ageism in cancer care has been highlighted as an
important problem that needs to be addressed (National Cancer
Equality Initiative, 2012; Lawler et al, 2014) and our results add to
the evidence for this. Clinicians need to ensure that older patients
do not undergo unnecessary and unjustified delays in treatment.
Research into the reasons for later treatment in older patients is
required.
The patterns of results found in this study need to be clarified
in other data sets, ideally with lower levels of missing stage, PS
and co-morbidity data. Our findings suggest that more deprived
patients are likely to appear more ill (as measured by PS) and the
‘sicker quicker’ effect may neutralise any patient and system
inequalities that might result in longer referral, diagnostic and
treatment intervals for these patients, potentially relating to
poorer communication and health literacy. Better evidence of
inequalities in health literacy by SEP, and the role this may have
in delay, is required. Investigation into patient and primary care
delay before GP referral, and of inequalities within these intervals,
is required.
CONCLUSIONS
In this cohort, the main factor determining timely post-primary
care referral, diagnosis and treatment for lung cancer was how sick
patients appeared. Improvements in meeting NICE time interval
targets were seen over time. However, older patients, who were
more likely to have poor PS, were less likely to receive treatment
within target, indicating possible age discrimination. It is possible
that the ‘sicker quicker’ effect may effectively ‘cancel out’ system
inequalities that might result in longer time intervals for more
deprived patients.
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